Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.60 |
| ▸ | CNR1 | P21554 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5570156 | 0.92 | CNR2 (0.56) | CNR2CNR1MEN1KMT2ATP53 | |
| SCHEMBL2746373 | 0.90 | CNR2 (0.62) | CNR2CNR1MEN1KMT2ATP53 | |
| SCHEMBL2745363 | 0.87 | CNR2 (0.45) | CNR2CNR1MEN1KMT2APDE10A | |
| SCHEMBL5570158 | 0.87 | CNR2 (0.56) | CNR2CNR1MEN1KMT2A | |
| SCHEMBL11907352 | 0.82 | CNR2 (0.58) | CNR2CNR1MEN1KMT2ATP53 | |
| SCHEMBL2746869 | 0.82 | CNR2 (0.51) | CNR2CNR1 | |
| SCHEMBL2746903 | 0.82 | CNR2 (0.57) | CNR2CNR1MEN1KMT2ATP53 | |
| SCHEMBL2747026 | 0.81 | CNR2 (0.61) | CNR2CNR1MEN1KMT2ATP53 | |
| SCHEMBL11907794 | 0.81 | CNR2 (0.43) | CNR2CNR1MEN1KMT2A | |
| SCHEMBL2745679 | 0.81 | CNR2 (0.63) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806342-B1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | CNR2 2/4885CNR1 1/4885MEN1 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.